<DOC>
	<DOCNO>NCT02662673</DOCNO>
	<brief_summary>Focal treatment localized prostate cancer aim destroy cancerous focus without damage surround tissue avoid side effect radical treatment . This focal treatment position alternative radical surgery well alternative active surveillance . This study feasibility study . It aim treat index tumor ( aggressive one ) determine vital prognosis patient , preserve maximum surround prostatic tissue preserve quality life . The expected result total destruction aggressive tumor area focal multifocal treatment strategy use Focal One® device ( EDAP-TMS , Vaulx-en-Velin , France ) . The tumor destruction validate negative biopsy rate 6 12 month post-treatment .</brief_summary>
	<brief_title>Evaluation Focal Treatments Localized Prostate Cancers With High Intensity Focused Ultrasound Using Focal One® Device</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Age 50 80 year ( inclusive ) life expectancy 5 year . PSA ≤ 10 ng / mL . Initial diagnosis localize prostate cancer ( stage T1 T2 ) . Diagnosis confirm multiparametric MRI subsequent systematic target prostate biopsy ( least 12 sextant biopsy two biopsy per MRI target ) . Identification primary cancer site ( index tumor ) possibly associate second independent tumor ( accessory tumor ) , provide tumor separate sextant median line . Maximum two cancer focus , one fulfilling follow condition Gleason score 6 AND biopsy invasion length ≥5 mm , OR Gleason score 6 AND correspond focal lesion MRI PIRADS ( Prostate Imaging Reporting Data System ) score ≥4/5 diameter ≥5 mm , OR Gleason score 7 ( 3+4 ) whatever biopsy invasion length MRI result may . Patient normal anal rectal anatomy . Patient condition correspond ASA ( American Society Anesthesiologists ) classification 1 2 . Patient treatment focal HIFU ( without perform associate TURP ) validate Multidisciplinary meeting . Accepting patient monitoring constraint define context study . Patient affiliate health insurance beneficiary similar plan . Patient ASA ( American Society Anesthesiologists ) score 3 . Patient clinical stage T3 . Metastatic distant ( CT and/or MRI ) lymph node . Patient two cancer focus . Patients already treated prostate cancer ( hormone therapy , radiotherapy , surgery ) . Patient distance rectal mucosa prostatic capsule 8 mm . History inflammatory bowel disease , rectal urinary tract fistula . History pelvic radiotherapy . History bladder cancer . History sclerosis bladder neck urethral stricture . Patient implant locate least 1 cm treatment zone ( stent , catheter ) . Hemorrhagic risk patient . Urogenital infection progress . Latex allergy . Allergy sulfur hexafluoride component SonoVue® . Patients recent acute coronary syndrome unstable ischemic heart disease : myocardial infarction phase formation evolution , typical angina rest within last 7 day , significant worsen cardiac symptom within last 7 day , recent intervention coronary artery factor suggest clinical instability ( eg recent ECG change , change clinical laboratory parameter ) , acute heart failure , heart failure stage III IV , severe rhythm disorder ( contraindication use SonoVue® ) . Patient right leave shunt , severe pulmonary hypertension ( pulmonary artery pressure &gt; 90 mm Hg ) , uncontrolled systemic hypertension . Patient respiratory distress syndrome . Patient severe chronic obstructive pulmonary disease . Patient acute endocarditis , prosthetic valve holder , acute systemic inflammation / sepsis , hyper coagulation status / recent thromboembolism . Patient life support suffer unstable neurological disease . Contraindication MRI ( pacemaker , metal prosthesis , etc ... ) . Patient participate participate another clinical study within last 30 day . Patient deprive liberty follow judicial administrative decision . Patient guardianship curatorship .</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>HIFU</keyword>
	<keyword>Prostate Cancer</keyword>
	<keyword>Focal</keyword>
	<keyword>Quality life</keyword>
	<keyword>Index study</keyword>
</DOC>